We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
FDA Selects Agilent’s Dual-Mode Platform for MAQC Project
News

FDA Selects Agilent’s Dual-Mode Platform for MAQC Project

FDA Selects Agilent’s Dual-Mode Platform for MAQC Project
News

FDA Selects Agilent’s Dual-Mode Platform for MAQC Project

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "FDA Selects Agilent’s Dual-Mode Platform for MAQC Project"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The U.S. Food and Drug Administration has recently selected Agilent’s dual-mode platform as part of its Microarray Quality Control (MAQC) project, designed to provide quality control guidance to the microarray industry.

"Our vision is to be able to assess the proficiency of a laboratory in running good microarray experiments," said Dr. Leming Shi, computational chemist, National Center for Toxicological Research, FDA, and architect of the MAQC project.

"We’re glad to see Agilent in the project, and we see positive responses to the one-color data from Agilent. Experimental design is unified, compared with other platforms, so there’s a lot of value in having two sample mixtures to evaluate the platform."

"This is the first one-color data I’ve ever generated, and I’m excited about using it to make research decisions," said FDA scientist Tucker Patterson, Ph.D.

"The workflow is very similar to the two-color work we’ve been doing, so there’s been no disruption caused by the new platform."

Advertisement